GLP-1 medicines: what they are, what they are not, and the risks worth understanding

GLP-1 receptor agonists are prescription medicines that imitate the action of a hormone released after eating. Depending on the medicine, they can improve blood-glucose control, reduce appetite, increase fullness and slow the rate at which the stomach empties.

Semaglutide and liraglutide act on the GLP-1 pathway. Tirzepatide acts on both GIP and GLP-1 receptors, although it is often discussed alongside GLP-1 medicines because its clinical use overlaps.

These effects can make a sustained energy deficit easier for some people. They do not make energy balance irrelevant, and they do not directly identify and remove body fat.

Brand names can create confusion. In the UK, Wegovy and Ozempic both contain semaglutide, but they are licensed for different purposes. Rybelsus is oral semaglutide for type 2 diabetes. Mounjaro contains tirzepatide and has licences that include type 2 diabetes and weight management in eligible adults.

They are not interchangeable consumer products. The correct medicine, dose and monitoring depend on the individual, other medication and the licensed indication. Starting, changing or stopping treatment belongs in a conversation with a qualified prescriber.

For an appropriate patient, GLP-1-based treatment can produce clinically meaningful improvements in weight and metabolic health. Lower appetite and greater fullness can reduce the constant negotiation around food that makes a calorie deficit difficult to maintain.

That is a legitimate physiological effect, not a lack of willpower and not “cheating”. Equally, the medicine is one tool within care. The best result is not simply the lowest number on the scale; it is improved health and function achieved with a plan the person can tolerate and sustain.

GLP-1 medicines do not choose body fat as the only tissue to be lost. They do not provide protein, micronutrients or a resistance-training stimulus. They do not automatically improve movement quality, strength, cardiovascular fitness or confidence in the gym.

They also do not teach the routines that may be needed if treatment changes or stops. Weight regain is possible after discontinuation, so maintenance, follow-up and the reasons behind any change in treatment should be planned with the prescribing team.

The UK Medicines and Healthcare products Regulatory Agency is explicit that these medicines are not a quick cosmetic weight-loss method. They should be prescribed for a licensed purpose and supplied through a regulated service.

When body weight falls substantially, some of the loss is often lean mass as well as fat mass. Body-composition studies of semaglutide and tirzepatide show that fat accounts for most of the measured loss on average, while absolute lean mass can also fall.

Lean mass is not identical to skeletal muscle: the measurement includes water and other non-fat tissue. It is therefore inaccurate to treat every kilogram of lean-mass change as lost muscle. The practical point remains that scale weight alone cannot tell us whether strength, function and nutritional status are being protected.

Progressive resistance training gives the body a reason to retain and use muscle. Adequate protein, overall diet quality and an appropriate rate of weight loss support that work. The exact plan should reflect age, health, training history, symptoms and clinical advice rather than a generic social-media target.

Nausea, vomiting, diarrhoea and constipation are common, particularly when treatment begins or the dose changes. Persistent vomiting or diarrhoea can lead to severe dehydration. Symptoms should be discussed with the prescribing service rather than managed by improvising the dose.

Acute pancreatitis is an infrequent but important risk across this class. Severe, persistent abdominal pain that may radiate to the back—especially with nausea or vomiting—requires urgent medical attention. Sudden changes in vision also require urgent assessment; UK guidance now includes a very rare optic-nerve condition associated with semaglutide.

This is not a complete side-effect list. The patient information leaflet for the specific medicine and the prescribing clinician should be the primary sources for individual risk.

These medicines should not be used during pregnancy, while trying to conceive or during breastfeeding. Tirzepatide can reduce the effectiveness of oral contraception for a period after starting treatment and after dose increases, so current product guidance should be followed.

Because the medicines delay stomach emptying, the surgical or anaesthetic team must know about their use before a procedure. Treatment should not be stopped without advice from the relevant healthcare professional.

Use a legitimate prescriber and registered pharmacy. Products sold through social media, beauty salons or unregulated websites may be counterfeit, incorrectly dosed or contain something different from the label. A request for a prescription without a proper consultation is a warning sign, not a convenience.

The medicine can change appetite and metabolic physiology. The clinical team manages indication, dosing, safety and other medication. Nutrition supports health and training. Resistance and aerobic work protect or develop physical capacity. These roles overlap, but they are not substitutes for one another.

For someone training while using a GLP-1 medicine, the programme may need to respond to reduced intake, nausea, fatigue or a quicker change in body mass. The aim is not to make every session maximally hard. It is to keep a safe, progressive signal in place while monitoring how the person is actually responding.

GLP-1 medicines can be highly useful for the right person and still require serious medical oversight. They are neither magic nor a moral failure. Their value depends on appropriate prescribing, tolerable risk and a wider plan that protects health, strength and long-term function.

If you are considering treatment or experiencing side effects, speak to a qualified prescriber. A personal trainer can support exercise and behaviour, but should not diagnose, prescribe or alter medication.